---
title: "SHENZHEN TRANSSION: H1 2026 net profit jumped 46.22% year-over-year, with strong growth in emerging markets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296129146.md"
description: "Revenue and net profit surged 21.85% and 46.22% year-over-year in H1 2026, driven by higher ASPs and strong performance in emerging markets. The company proposed a significant cash dividend and continues to invest in R&D and international expansion.Original document: Shenzhen Transsion Holdings Co., Ltd. Class A [688036] Interim report — Aug. 17 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-17T16:05:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296129146.md)
  - [en](https://longbridge.com/en/news/296129146.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296129146.md)
generator: "portal-rs"
---

# SHENZHEN TRANSSION: H1 2026 net profit jumped 46.22% year-over-year, with strong growth in emerging markets

Revenue and net profit surged 21.85% and 46.22% year-over-year in H1 2026, driven by higher ASPs and strong performance in emerging markets. The company proposed a significant cash dividend and continues to invest in R&D and international expansion.

Original document: Shenzhen Transsion Holdings Co., Ltd. Class A \[688036\] Interim report — Aug. 17 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [688036.CN](https://longbridge.com/en/quote/688036.CN.md)

## Related News & Research

- [Transsion Holdings Receives CSRC Filing for HK Listing: Report](https://longbridge.com/en/news/296044874.md)
- [EY is turning its internships into yearlong residencies as AI changes entry-level work](https://longbridge.com/en/news/296111390.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [BEWI: Q2 2026 delivered double-digit sales and EBITDA growth, with strong performance across all segments](https://longbridge.com/en/news/296303987.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**